All In Biotech

Drug Trial Radar · NCT07581002

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 2032

Study completion Jun 2032

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood cell production. This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA) in adult participants with AML ineligible to receive intensive chemotherapy. Pivekimab sunirine is a drug being evaluated in the treatment of AML.This is a Phase 2/Phase 3, study of PVEK. Phase 2 is open-label and randomized. Phase 3 is double-blind, randomized. Phase 2 and Phase 3 studies test potential new treatments in patients with a condition or disease. Open-label means that both patients and study doctors know which study treatment is given to patients in Phase 2 of the study. Double-blind means that neither the patients nor the study doctors know who is given which study treatment in Phase 3 of the study. Approximately 660 adult participants will be enrolled in 180 sites worldwide. In Phase 2 of the study, patients will be randomized to receive PVEK + VEN + AZA or standard of care treatment with VEN + AZA. In Phase 3, patients will be randomized to receive PVEK + VEN + AZA or a matching-placebo for PVEK plus VEN + AZA. PVEK is given as an infusion into the vein, AZA is given as an injection under your skin (subcutaneous) or as an infusion into the vein (intravenous) (depending on country where patient enrolls), and VEN is a tablet given by mouth. The total study duration is approximately 71 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Pivekimab SunirineDrug

    Intravenous

  • VenetoclaxDrug

    Orally

  • AzacitidineDrug

    Intravenous Or Subcutaneous

  • Matching Placebo for PVEKDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Complete remission (CR)Time frame: Up to Approximately 71 Months
  2. Phase 3: Complete remission (CR)Time frame: Up to Approximately 71 Months
  3. Phase 3: Overall Survival (OS)Time frame: Up to Approximately 71 Months
  4. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 71 months

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 279568

    Duarte, California · Recruiting

  • Moffitt Cancer Center /ID# 279192

    Tampa, Florida · Recruiting

  • Winship Cancer Institute of Emory University /ID# 279006

    Atlanta, Georgia · Recruiting

  • Washington University /ID# 280295

    St Louis, Missouri · Recruiting

  • Montefiore Medical Center - Moses Campus /ID# 279399

    The Bronx, New York · Recruiting

  • Penn Medicine University of Pennsylvania Health System /ID# 279382

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 279402

    Houston, Texas · Recruiting

  • Medizinische Universitaet Wien /ID# 278825

    Vienna, Austria · Recruiting

  • Universitaetsklinikum St. Poelten /ID# 278835

    Sankt Pölten, Lower Austria, Austria · Recruiting

  • Hanusch-Krankenhaus /ID# 279467

    Vienna, State of Vienna, Austria · Recruiting

  • Medizinische Universitaet Graz /ID# 278830

    Graz, Styria, Austria · Recruiting

  • Ordensklinikum Linz Elisabethinen /ID# 278824

    Linz, Upper Austria, Austria · Recruiting

  • Hopital Saint-Louis /ID# 279032

    Paris, France · Recruiting

  • Chu De Nice-Hopital Larchet II /ID# 278998

    Nice, Alpes-Maritimes, France · Recruiting

  • Institut Paoli-Calmettes /ID# 279015

    Marseille, Bouches-du-Rhone, France · Recruiting

  • Centre Hospitalier Universitaire de Bordeaux /ID# 279001

    Pessac, New Aquitaine, France · Recruiting

  • Centre Hospitalier Universitaire D'Angers /ID# 280390

    Angers, Pays de la Loire Region, France · Recruiting

  • CHU Amiens-Picardie Site Sud /ID# 280716

    Amiens, Somme, France · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 278719

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center /ID# 278712

    Jerusalem, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 278866

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center /ID# 278714

    Petah Tikva, Central District, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 278717

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Seoul National University Bundang Hospital /ID# 279634

    Seongnam-si, Gyeonggido, South Korea · Recruiting

  • Seoul National University Hospital /ID# 279396

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Yonsei University Health System - Severance Hospital /ID# 279933

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Asan Medical Center /ID# 279395

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Samsung Medical Center /ID# 279397

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Hospital General Universitario Gregorio Maranon /ID# 279479

    Madrid, Spain · Recruiting

  • Hospital MD Anderson Cancer Center Madrid /ID# 279480

    Madrid, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal /ID# 279638

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia /ID# 279635

    Valencia, Spain · Recruiting

  • Hospital Universitario Puerta De Hierro /ID# 279660

    Majadahonda, Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra - Pamplona /ID# 279516

    Pamplona, Navarre, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio /ID# 279471

    Seville, Sevilla, Spain · Recruiting

  • China Medical University Hospital /ID# 279261

    Taichung, Taiwan · Recruiting

  • Taichung Veterans General Hospital /ID# 279296

    Taichung, Taiwan · Recruiting

  • National Taiwan University Hospital /ID# 279289

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital /ID# 281480

    Taipei, Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital /ID# 279294

    Taoyuan City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.